A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, ...

Secondary polycythemia, also known as secondary erythrocytosis or secondary erythrocythemia, is a rare condition in which your body produces an excess amount of red blood cells. This overproduction of ...

Polycythemia vera (PV) is a rare blood cancer causing the bone marrow to make too many blood cells. Treatment usually starts with phlebotomy and may continue with medications. If one treatment isn’t ...

PV management requires balancing thrombotic risk reduction with quality of life preservation, often involving trade-offs. JAK/STAT pathway activation contributes to chronic inflammation and symptom ...

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best ...

Polycythemia vera (PV) is a disorder in which the bone marrow produces too many blood cells, leading to blood clots, bleeding, or an enlarged spleen. PV has a reduced life expectancy due to the ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

There is currently no cure for polycythemia vera (PV), but researchers are looking at new treatments that may help better manage and control the progression of the condition. Polycythemia vera (PV) is ...

Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the ...